SIKVAV promotion proliferation of vascular endothelial cells and related mechanisms.

IF 1 4区 医学 Q4 ENGINEERING, BIOMEDICAL
Xionglin Chen, Jie Zhang, Xiaoming Cao, He Jiang, Zhiren Wu, Zi du Zeng, Chen Jiang, Hui Chen
{"title":"SIKVAV promotion proliferation of vascular endothelial cells and related mechanisms.","authors":"Xionglin Chen, Jie Zhang, Xiaoming Cao, He Jiang, Zhiren Wu, Zi du Zeng, Chen Jiang, Hui Chen","doi":"10.3233/BME-240018","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Vascular endothelial injury, a key factor in diabetic foot ulcers (DFUs) pathogenesis, is linked to the impaired proliferation and migration of vascular endothelial cells, modulated by hypoxia-inducible factor, growth factors, and inflammatory elements.</p><p><strong>Objective: </strong>The present study assesses the role of SIKVAV (Ser-Ile-Lys-Val-Ala-Val), a peptide shown to enhance cell proliferation and migration, on mouse aortic endothelial cell (MAEC) and the corresponding molecular mechanisms.</p><p><strong>Methods: </strong>MAEC were treated with SIKVAV at 0, 100, 200, 400, and 600 μg/mL for 0, 24, 48, and 72 h. Cell viability was tested using the CCK-8 assay. Proliferating cell nuclear antigen (PCNA), extracellular signal-regulated kinase 1/2 (ERK1/2), and protein kinase B (Akt) levels were measured by qRT-PCR and western blot.</p><p><strong>Results: </strong>SIKVAV augmented PCNA mRNA expression and stimulated vascular endothelial cell proliferation in a concentration and time-dependent fashion. Furthermore, it amplified the expression of p-ERK1/2 and p-Akt, pivotal components of the mitogen-activated protein kinase (MAPK)/ERK1/2 and phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathways. The inhibition of these pathways suppressed PCNA mRNA expression, cell proliferation rate, and decreased p-ERK1/2 and p-Akt levels, highlighting SIKVAV's role in promoting vascular endothelial cell proliferation via these pathways.</p><p><strong>Conclusion: </strong>The results of this study confirmed that SIKVAV grafted onto scaffolds can accelerate the proliferation of vascular endothelial cells for the therapy of skin wounds, and provide a theoretical basis for its application in ischemic disease as synthesized biomaterials scaffolds of tissue engineering.</p>","PeriodicalId":9109,"journal":{"name":"Bio-medical materials and engineering","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bio-medical materials and engineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3233/BME-240018","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Vascular endothelial injury, a key factor in diabetic foot ulcers (DFUs) pathogenesis, is linked to the impaired proliferation and migration of vascular endothelial cells, modulated by hypoxia-inducible factor, growth factors, and inflammatory elements.

Objective: The present study assesses the role of SIKVAV (Ser-Ile-Lys-Val-Ala-Val), a peptide shown to enhance cell proliferation and migration, on mouse aortic endothelial cell (MAEC) and the corresponding molecular mechanisms.

Methods: MAEC were treated with SIKVAV at 0, 100, 200, 400, and 600 μg/mL for 0, 24, 48, and 72 h. Cell viability was tested using the CCK-8 assay. Proliferating cell nuclear antigen (PCNA), extracellular signal-regulated kinase 1/2 (ERK1/2), and protein kinase B (Akt) levels were measured by qRT-PCR and western blot.

Results: SIKVAV augmented PCNA mRNA expression and stimulated vascular endothelial cell proliferation in a concentration and time-dependent fashion. Furthermore, it amplified the expression of p-ERK1/2 and p-Akt, pivotal components of the mitogen-activated protein kinase (MAPK)/ERK1/2 and phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathways. The inhibition of these pathways suppressed PCNA mRNA expression, cell proliferation rate, and decreased p-ERK1/2 and p-Akt levels, highlighting SIKVAV's role in promoting vascular endothelial cell proliferation via these pathways.

Conclusion: The results of this study confirmed that SIKVAV grafted onto scaffolds can accelerate the proliferation of vascular endothelial cells for the therapy of skin wounds, and provide a theoretical basis for its application in ischemic disease as synthesized biomaterials scaffolds of tissue engineering.

SIKVAV 促进血管内皮细胞增殖及其相关机制。
背景:血管内皮损伤是糖尿病足溃疡(DFUs)发病机制中的一个关键因素,它与血管内皮细胞的增殖和迁移受损有关,并受缺氧诱导因子、生长因子和炎症因子的调节:本研究评估了 SIKVAV(Ser-Ile-Lys-Val-Ala-Val)对小鼠主动脉内皮细胞(MAEC)的作用及相应的分子机制:用 0、100、200、400 和 600 μg/mL 的 SIKVAV 处理小鼠主动脉内皮细胞 0、24、48 和 72 小时。增殖细胞核抗原(PCNA)、细胞外信号调节激酶1/2(ERK1/2)和蛋白激酶B(Akt)水平通过qRT-PCR和Western印迹进行检测:结果:SIKVAV能增强PCNA mRNA的表达,并以浓度和时间依赖性的方式刺激血管内皮细胞增殖。此外,它还增加了 p-ERK1/2 和 p-Akt 的表达,p-ERK1/2 和 p-Akt 是丝裂原活化蛋白激酶(MAPK)/ERK1/2 和磷脂酰肌醇-3-激酶(PI3K)/Akt 信号通路的关键成分。对这些通路的抑制抑制了 PCNA mRNA 的表达、细胞增殖率以及 p-ERK1/2 和 p-Akt 水平的降低,突出了 SIKVAV 通过这些通路促进血管内皮细胞增殖的作用:本研究结果证实,将 SIKVAV 移植到支架上可加速血管内皮细胞增殖,用于治疗皮肤创伤,并为其作为组织工程的合成生物材料支架应用于缺血性疾病提供了理论依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Bio-medical materials and engineering
Bio-medical materials and engineering 工程技术-材料科学:生物材料
CiteScore
1.80
自引率
0.00%
发文量
73
审稿时长
6 months
期刊介绍: The aim of Bio-Medical Materials and Engineering is to promote the welfare of humans and to help them keep healthy. This international journal is an interdisciplinary journal that publishes original research papers, review articles and brief notes on materials and engineering for biological and medical systems. Articles in this peer-reviewed journal cover a wide range of topics, including, but not limited to: Engineering as applied to improving diagnosis, therapy, and prevention of disease and injury, and better substitutes for damaged or disabled human organs; Studies of biomaterial interactions with the human body, bio-compatibility, interfacial and interaction problems; Biomechanical behavior under biological and/or medical conditions; Mechanical and biological properties of membrane biomaterials; Cellular and tissue engineering, physiological, biophysical, biochemical bioengineering aspects; Implant failure fields and degradation of implants. Biomimetics engineering and materials including system analysis as supporter for aged people and as rehabilitation; Bioengineering and materials technology as applied to the decontamination against environmental problems; Biosensors, bioreactors, bioprocess instrumentation and control system; Application to food engineering; Standardization problems on biomaterials and related products; Assessment of reliability and safety of biomedical materials and man-machine systems; and Product liability of biomaterials and related products.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信